Santarus' Patents For Heartburn Drug Invalid: Judge

Law360, New York (April 15, 2010, 1:55 PM EDT) -- In an infringement suit against Par Pharmaceutical Inc. over its efforts to introduce a generic version of Zegerid, a federal judge has ruled that patents held by the University of Missouri and licensed to Santarus Inc. for the heartburn drug are invalid due to obviousness.

Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware on Wednesday held that the five patents related to Zegerid were invalid as obvious in light of prior art.

However, the judge rejected Par's claims that the...
To view the full article, register now.